{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T11:26:27Z","timestamp":1794137187434,"version":"4.8.0"},"reference-count":136,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.atherosclerosis.2023.04.012","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T11:19:38Z","timestamp":1682680778000},"page":"107-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":116,"special_numbering":"C","title":["Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society"],"prefix":"10.1016","volume":"374","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2229-1120","authenticated-orcid":false,"given":"Florian","family":"Kronenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik S.G.","family":"Stroes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Ference","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit J.","family":"Arsenault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Berglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc R.","family":"Dweck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlys L.","family":"Koschinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Mach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine J.","family":"McNeal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Moriarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Natarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f8rge G.","family":"Nordestgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus G.","family":"Parhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim S.","family":"Virani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"von Eckardstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane K.","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lale S.","family":"Tokg\u00f6zo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib1","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2022.04.003","article-title":"Lipoprotein(a) beyond the kringle IV repeat polymorphism: the complexity of genetic variation in the LPA gene","volume":"349","author":"Coassin","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2022.04.015","article-title":"Lipoprotein(a) and cardiovascular and valvular diseases: a genetic epidemiological perspective","volume":"349","author":"Arsenault","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib4","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib5","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib6","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O'Donoghue","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib7","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels","volume":"327","author":"Nissen","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib8","first-page":"829","article-title":"Lipoprotein(a) in women twins: heritability and relationship to apolipoprotein(a) phenotypes","volume":"51","author":"Austin","year":"1992","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0021-9150(91)90191-5","article-title":"The NHLBI Twin Study: heritability of apolipoprotein A-I and B, and low density lipoprotein subclasses and concordance for lipoprotein(a)","volume":"91","author":"Lamon-Fava","year":"1991","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib10","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1126\/science.2530631","article-title":"The mysteries of lipoprotein(a)","volume":"246","author":"Utermann","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib11","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1172\/JCI113093","article-title":"Lp(a) glycoprotein phenotypes: inheritance and relation to Lp(a)-lipoprotein concentrations in plasma","volume":"80","author":"Utermann","year":"1987","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib12","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1172\/JCI115248","article-title":"Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis","volume":"87","author":"Lackner","year":"1991","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib13","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/BF00220066","article-title":"The apolipoprotein(a) gene: a transcribed hypervariable locus controlling plasma lipoprotein(a) concentration","volume":"90","author":"Kraft","year":"1992","journal-title":"Hum. Genet."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/cvr\/cvu107","article-title":"Lipoprotein(a) concentrations, apolipoprotein(a) phenotypes and peripheral arterial disease in three independent cohorts","volume":"103","author":"Laschkolnig","year":"2014","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib15","doi-asserted-by":"crossref","first-page":"9060","DOI":"10.1016\/S0021-9258(17)37076-X","article-title":"Molecular basis for null lipoprotein(a) phenotypes and the influence of apolipoprotein(a) size on plasma lipoprotein(a) level in the baboon","volume":"269","author":"White","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib16","doi-asserted-by":"crossref","first-page":"32403","DOI":"10.1074\/jbc.271.50.32403","article-title":"The number of identical kringle IV repeats in apolipoprotein(a) affects its processing and secretion by HepG2 cells","volume":"271","author":"Brunner","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib17","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib18","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1194\/jlr.M076232","article-title":"A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms","volume":"58","author":"Mack","year":"2017","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/joim.12207","article-title":"Genetic determination of lipoprotein(a) and its association with cardiovascular disease. Convenient does not always mean better","volume":"276","author":"Kronenberg","year":"2014","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib20","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jacc.2021.05.037","article-title":"Frequent LPA KIV-2 variants lower lipoprotein(a) concentrations and protect against coronary artery disease","volume":"78","author":"Schachtl-Riess","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib21","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1093\/eurheartj\/ehx174","article-title":"A novel but frequent variant in LPA KIV-2 is associated with a pronounced Lp(a) and cardiovascular risk reduction","volume":"38","author":"Coassin","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib22","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1161\/ATVBAHA.120.315300","article-title":"Genome-wide association study and identification of a protective missense variant on lipoprotein(a) concentration: protective missense variant on lipoprotein(a) concentration-brief report","volume":"41","author":"Said","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2022.04.006","article-title":"Non-genetic influences on lipoprotein(a) concentrations","volume":"349","author":"Enkhmaa","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib24","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1523-1755.2004.00418.x","article-title":"The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome","volume":"65","author":"Kronenberg","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib25","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s10157-013-0875-8","article-title":"Causes and consequences of lipoprotein(a) abnormalities in kidney disease","volume":"18","author":"Kronenberg","year":"2014","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib26","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/bmj.304.6826.545","article-title":"Lipoprotein(a) in cirrhosis","volume":"304","author":"Feely","year":"1992","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib27","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.atherosclerosis.2022.06.1023","article-title":"Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: the Copenhagen General Population Study","volume":"355","author":"Simony","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib28","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/ajcn\/nqab287","article-title":"Effects of a low-carbohydrate diet on insulin-resistant dyslipoproteinemia-a randomized controlled feeding trial","volume":"115","author":"Ebbeling","year":"2022","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/15438627.2016.1191488","article-title":"Aerobic, resistance and combined training and detraining on body composition, muscle strength, lipid profile and inflammation in coronary artery disease patients","volume":"24","author":"Theodorou","year":"2016","journal-title":"Res. Sports Med."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib30","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2337\/diacare.16.2.421","article-title":"The relationship of physical fitness to lipid and lipoprotein(a) levels in adolescents with IDDM","volume":"16","author":"Austin","year":"1993","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib31","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib32","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2022.04.013","article-title":"Mendelian randomization: principles and its usage in lp(a) research","volume":"349","author":"Lamina","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib33","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/MOL.0000000000000855","article-title":"Consensus and guidelines on lipoprotein(a) - seeing the forest through the trees","volume":"33","author":"Kronenberg","year":"2022","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib34","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10557-016-6648-3","article-title":"Human genetics and the causal role of lipoprotein(a) for various diseases","volume":"30","author":"Kronenberg","year":"2016","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib35","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/01.ATV.12.10.1214","article-title":"Apo(a) isoforms predict risk for coronary heart disease: a study in six populations","volume":"12","author":"Sandholzer","year":"1992","journal-title":"Arterioscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib36","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1161\/01.ATV.16.6.713","article-title":"Apolipoprotein(a) Kringle IV repeat number predicts risk for coronary heart disease","volume":"16","author":"Kraft","year":"1996","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib37","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004494","article-title":"Distribution and medical impact of loss-of-function variants in the Finnish founder population","volume":"10","author":"Lim","year":"2014","journal-title":"PLoS Genet."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib39","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2019.10.019","article-title":"Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes","volume":"74","author":"Gudbjartsson","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib40","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"Cardiovascular risk collaboration, SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib41","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American heart association task force on practice guidelines","volume":"63","author":"Goff","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.atherosclerosis.2016.11.010","article-title":"Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: the EPIC-Norfolk prospective population study","volume":"256","author":"Perrot","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib43","first-page":"1129","article-title":"Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib44","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","author":"Mach","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib45","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a) - resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib46","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jacc.2021.12.016","article-title":"Managing atherosclerotic cardiovascular risk in young adults: JACC state-of-the-art review","volume":"79","author":"Stone","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib47","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41569-019-0325-8","article-title":"Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care","volume":"17","author":"Watts","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib48","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.121.003489","article-title":"Genome-wide characterization of a highly penetrant form of hyperlipoprotein(a)emia associated with genetically elevated cardiovascular risk","volume":"15","author":"Coassin","year":"2022","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib49","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.jacc.2022.09.021","article-title":"Equivalent impact of elevated lipoprotein(a) and familial hypercholesterolemia in patients with atherosclerotic cardiovascular disease","volume":"80","author":"Hedegaard","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib50","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national Biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib51","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1093\/eurjpc\/zwaa063","article-title":"Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions","volume":"28","author":"Welsh","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib52","first-page":"78","article-title":"Elevated lipoprotein(a) levels, LPA risk genotypes, and increased risk of heart failure in the general population","volume":"4","author":"Kamstrup","year":"2016","journal-title":"J. Am. Coll. Cardiol. Heart Fail"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib53","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1161\/STROKEAHA.119.026872","article-title":"Causal effect of Lp(a) [lipoprotein(a)] level on ischemic stroke and alzheimer disease a mendelian randomization study","volume":"50","author":"Pan","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib54","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1093\/eurheartj\/ehab081","article-title":"Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study","volume":"42","author":"Arnold","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib55","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jacc.2018.06.046","article-title":"Impact of lipids on cardiovascular health: JACC health promotion series","volume":"72","author":"Ference","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib56","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1161\/ATVBAHA.120.314856","article-title":"Genome-wide polygenic score, clinical risk factors, and long-term trajectories of coronary artery disease","volume":"40","author":"Hindy","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib57","first-page":"e93","article-title":"Polygenic risk scores for cardiovascular disease: a scientific statement from the American heart association","volume":"146","author":"O'Sullivan","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib58","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.atherosclerosis.2022.04.005","article-title":"Lipoprotein(a) and ethnicities","volume":"349","author":"Mehta","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib59","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/CIRCULATIONAHA.111.045120","article-title":"Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"125","author":"Virani","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib60","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1161\/ATVBAHA.114.304785","article-title":"Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis, Arterioscler","volume":"35","author":"Guan","year":"2015","journal-title":"Thromb. Vasc. Biol"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib61","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","article-title":"Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups","volume":"139","author":"Pare","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib62","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/eurjpc\/zwac271","article-title":"Lipoprotein(a)-related cardiovascular and all-cause mortalities in Korean adults","volume":"30","author":"Kim","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100053","article-title":"Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements","volume":"62","author":"Yeang","year":"2021","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib64","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib65","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib66","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lp(a) (Lipoprotein[a])-Lowering by 50 mg\/dL (105 nmol\/L) may Be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib67","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jacc.2013.06.051","article-title":"Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (atherothrombosis intervention in metabolic syndrome with low HDL\/high triglyceride and impact on global health outcomes)","volume":"62","author":"Albers","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib68","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1093\/eurheartj\/ehy902","article-title":"High lipoprotein(a) and high risk of mortality","volume":"40","author":"Langsted","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib69","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated lipoprotein(a) and risk of ischemic stroke","volume":"74","author":"Langsted","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib70","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib71","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.jacl.2018.08.012","article-title":"Lipoprotein(a) and secondary prevention of atherothrombotic events: a critical appraisal","volume":"12","author":"Boffa","year":"2018","journal-title":"J. Clin. Lipidol"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib72","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jacc.2013.09.042","article-title":"Lipoprotein(a) for risk assessment in patients with established coronary artery disease","volume":"63","author":"O'Donoghue","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib73","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12944-019-1092-6","article-title":"Prognostic value of lipoprotein (a) level in patients with coronary artery disease: a meta-analysis","volume":"18","author":"Wang","year":"2019","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib74","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/clinchem\/hvac094","article-title":"The curious case of synergy between lipoprotein (a), coronary calcification, and cardiovascular disease risk","volume":"68","author":"Almarzooq","year":"2022","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib75","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jacc.2021.11.058","article-title":"Independent association of lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk","volume":"79","author":"Mehta","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib76","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib77","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.atherosclerosis.2022.04.009","article-title":"Beyond fibrinolysis: the confounding role of Lp(a) in thrombosis","volume":"349","author":"Boffa","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib78","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1194\/jlr.P094763","article-title":"Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis","volume":"60","author":"Boffa","year":"2019","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib79","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/eurheartj\/ehaa171","article-title":"Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a)","volume":"41","author":"Stiekema","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib80","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1093\/eurheartj\/ehy862","article-title":"Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin\/kexin type 9 antibody treatment","volume":"40","author":"Stiekema","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib81","first-page":"26","article-title":"Vulnerable plaque, characteristics, detection, and potential therapies","volume":"6","author":"Hafiane","year":"2019","journal-title":"J Cardiovasc Dev Dis"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib82","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.3324\/haematol.2018.211433","article-title":"Recurrent stroke: the role of thrombophilia in a large international pediatric stroke population","volume":"104","author":"deVeber","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib83","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V94.11.3678","article-title":"Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood","volume":"94","author":"Nowak-G\u00f6ttl","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib84","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/ijs.12136","article-title":"Review of lipid and lipoprotein(a) abnormalities in childhood arterial ischemic stroke","volume":"9","author":"Sultan","year":"2014","journal-title":"Int. J. Stroke"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib85","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1093\/eurheartj\/ehab251","article-title":"Elevated lipoprotein(a) and the risk of stroke in children, young adults, and the elderly","volume":"42","author":"Tsimikas","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib86","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.atherosclerosis.2022.04.008","article-title":"Lipoprotein(a) measurement issues: are we making a mountain out of a molehill?","volume":"349","author":"Kronenberg","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib87","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.atherosclerosis.2019.08.015","article-title":"Comparison of lipoprotein(a) serum concentrations measured by six commercially available immunoassays","volume":"289","author":"Scharnagl","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib88","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/clinchem\/41.2.246","article-title":"Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a)","volume":"41","author":"Marcovina","year":"1995","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib89","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.atherosclerosis.2019.08.019","article-title":"The challenges of measuring Lp(a): a fight against Hydra?","volume":"289","author":"Kronenberg","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib90","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/clinchem\/hvaa239","article-title":"Towards an SI-traceable reference measurement system for seven serum apolipoproteins using bottom-up quantitative proteomics: conceptual approach enabled by cross-disciplinary\/cross-sector collaboration","volume":"67","author":"Cobbaert","year":"2021","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib91","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/clinchem\/hvaa324","article-title":"Development of an LC-MS\/MS proposed candidate reference method for the standardization of analytical methods to measure lipoprotein(a)","volume":"67","author":"Marcovina","year":"2021","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib92","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/clinchem\/hvac203","article-title":"Commutability assessment of candidate reference materials for lipoprotein(a) by comparison of a MS-based candidate reference measurement procedure with immunoassays","volume":"69","author":"Dikaios","year":"2023","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib93","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/clinchem\/hvac204","article-title":"Development of an LC-MRM-MS-based candidate reference measurement procedure for standardization of serum apolipoprotein (a) tests","volume":"69","author":"Ruhaak","year":"2023","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib94","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jacl.2018.07.003","article-title":"Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size","volume":"12","author":"Tsimikas","year":"2018","journal-title":"J. Clin. Lipidol"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib95","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026762","article-title":"Temporal trends in lipoprotein(a) concentrations: the atherosclerosis risk in communities study","volume":"11","author":"Deshotels","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib96","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jacc.2021.11.055","article-title":"Repeat measures of lipoprotein(a) molar concentration and cardiovascular risk","volume":"79","author":"Trinder","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib97","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/eurheartj\/ehz776","article-title":"Statins and increases in Lp(a): an inconvenient truth that needs attention","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib98","first-page":"1399","article-title":"Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation, Arterioscler","volume":"14","author":"Kronenberg","year":"1994","journal-title":"Thromb"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib99","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/164_2021_504","article-title":"Lipoprotein(a)","volume":"270","author":"Kronenberg","year":"2022","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib100","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1093\/cvr\/cvab247","article-title":"The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors","volume":"118","author":"Blanchard","year":"2022","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib101","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1210\/clinem\/dgab734","article-title":"Lipoprotein(a) levels at birth and in early childhood: the COMPARE study","volume":"107","author":"Strandkjaer","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib102","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.atherosclerosis.2022.03.004","article-title":"Lipoprotein(a) levels from childhood to adulthood: data in nearly 3,000 children who visited a pediatric lipid clinic","volume":"349","author":"de Boer","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib103","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2022.07.009","article-title":"Long-term tracking and population characteristics of lipoprotein (a) in the cardiovascular risk in young Finns study","volume":"356","author":"Raitakari","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib104","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1161\/CIRCULATIONAHA.109.913673","article-title":"Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies","volume":"121","author":"Kenet","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib105","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association","volume":"13","author":"Wilson","year":"2019","journal-title":"J. Clin. Lipidol"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib106","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/S0022-2275(20)32100-3","article-title":"Preparation of a stable fresh frozen primary lipoprotein[a] (Lp[a]) standard","volume":"40","author":"Kostner","year":"1999","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib107","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1093\/clinchem\/46.12.1956","article-title":"Use of a reference material proposed by the international federation of clinical chemistry and laboratory medicine to evaluate analytical methods for the determination of plasma lipoprotein(a)","volume":"46","author":"Marcovina","year":"2000","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib108","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.cca.2011.05.036","article-title":"Lipoprotein(a)-cholesterol: a significant component of serum cholesterol","volume":"412","author":"Kinpara","year":"2011","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib109","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1523-1755.2004.00737.x","article-title":"Lipoprotein(a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome: impact on lipid-lowering therapy?","volume":"66","author":"Kronenberg","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib110","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib111","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S2213-8587(16)30042-0","article-title":"High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study","volume":"4","author":"Langsted","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib112","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1373\/clinchem.2019.306738","article-title":"Effect of lipoprotein(a) on the diagnosis of familial hypercholesterolemia: does it make a difference in the clinic?","volume":"65","author":"Chan","year":"2019","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib113","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.atherosclerosis.2021.08.009","article-title":"Lipoprotein(a) in hereditary hypercholesterolemia: influence of the genetic cause, defective gene and type of mutation","volume":"349","author":"Marco-Benedi","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib114","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/eurheartj\/ehs344","article-title":"Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study","volume":"34","author":"Hopewell","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib115","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0021-9150(89)90218-9","article-title":"Transient changes of serum lipoprotein(a) as an acute phase protein","volume":"78","author":"Maeda","year":"1989","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib116","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1161\/01.CIR.0000130844.01174.55","article-title":"Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein","volume":"109","author":"Tsimikas","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib117","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1161\/01.ATV.20.4.1137","article-title":"Major reduction in plasma Lp(a) levels during sepsis and burns","volume":"20","author":"Mooser","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib118","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.atherosclerosis.2021.12.008","article-title":"Lipoprotein(a), venous thromboembolism and COVID-19: a pilot study","volume":"341","author":"Nurmohamed","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib119","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.atherosclerosis.2021.11.029","article-title":"Elevated lipoprotein(a) in mitral and aortic valve calcification and disease: the Copenhagen General Population Study","volume":"349","author":"Kaltoft","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib120","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1172\/JCI116213","article-title":"Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a)","volume":"91","author":"Dieplinger","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib121","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1161\/ATVBAHA.116.307983","article-title":"Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 Years of follow-up and apolipoprotein(a) characterization","volume":"36","author":"Roeseler","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"Suppl 1","key":"10.1016\/j.atherosclerosis.2023.04.012_bib122","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/1744-9987.13780","article-title":"The German Lipoprotein Apheresis Registry-Summary of the ninth annual report","volume":"26","author":"Schettler","year":"2022","journal-title":"Ther. Apher. Dial."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib123","first-page":"16","article-title":"Lipoprotein apheresis: first FDA indicated treatment for elevated lipoprotein(a)","volume":"1","author":"Nugent","year":"2020","journal-title":"J. Clin. Cardiol"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib124","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib125","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib126","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.atherosclerosis.2019.06.896","article-title":"Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: pooled analysis of alirocumab phase 3 trials","volume":"288","author":"Ray","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib127","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib128","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.atherosclerosis.2019.07.001","article-title":"Statin treatment increases lipoprotein(a) levels in subjects with low molecular weight apolipoprotein(a) phenotype","volume":"289","author":"Yahya","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib129","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib130","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/eurjpc\/zwab171","article-title":"Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis","volume":"29","author":"de Boer","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib131","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/13543784.2020.1757070","article-title":"Gene-based therapy in lipid management: the winding road from promise to practice","volume":"29","author":"Tromp","year":"2020","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib132","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.atherosclerosis.2022.04.016","article-title":"Lipoprotein (a) and diabetes mellitus","volume":"349","author":"Lamina","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib133","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.atherosclerosis.2008.07.019","article-title":"Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy","volume":"203","author":"Chasman","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib134","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jacc.2022.07.027","article-title":"Aspirin for primary prevention of cardiovascular events in relation to lipoprotein(a) genotypes","volume":"80","author":"Lacaze","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib135","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1161\/ATVBAHA.112.248765","article-title":"Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis","volume":"32","author":"Kamstrup","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2023.04.012_bib136","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191502300182X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191502300182X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:52:00Z","timestamp":1758156720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002191502300182X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":136,"alternative-id":["S002191502300182X"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.04.012","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}